Envision Pharma Group

Company Overview

Founded in 2001, Envision Pharma Group (“Envision”) is an innovative global technology and medical affairs company serving the world’s leading pharmaceutical, biotechnology and medical device companies. Envision offers an attractive blend of solutions including strategic publication planning and related data dissemination and consultancy services, enhanced with industry-leading complementary technology solutions. At the time of Halifax’s exit, Envision had five offices, two in the United Kingdom and three in the United States, Philadelphia, PA, Southport, CT, and Glastonbury, CT. Envision provided services and product solutions to many biopharma companies, including 18 of the top 20 pharmaceutical companies.

Opportunities

• Facilitate management buyout from current corporate owner
• Partner with a strong management team eager to operate as a stand-alone business to accelerate growth and advance the company’s position as a leader in the global publications planning and technology sector

Key ValuFactors Initiatives

• Developed a novel strategy to amplify growth and address larger international opportunity in pharma services and medical communications
• Modernized legacy software platform and launched six new modules
• Expanded into three new services lines that rounded out the company’s therapeutic expertise
• Completed three add-on acquisitions, the company’s first, adding new geographies and service breadth
• Repositioned the business to address broader $25 billion market

Outcome

During the course of the partnership, Halifax and management grew revenue and EBITDA by 52% and 88% respectively, exceeding projections and accomplishing their 5-year growth plan in two and a half years.

After a three-year partnership, Halifax successfully exited Envision through a sale to financial sponsors. The company’s founders achieved their goals of completing a corporate carve out and continued to run the business following the sale.